Is this the best way to cash in on the weight-loss gold rush?

Viking should have plenty of news to share with investors this year.

Viking Therapeutics Inc. VKTX shares are up on Monday, in reaction to data from Novo Nordisk A/S’ NVO REDEFINE 4 Phase 3 ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best US stocks to buy under $50. On January 12, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced a significant milestone in the development of ...

Viking has a market value of about $3.5 billion, leaving it room to run if it gains product approvals and then goes on to ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names ...

It brings the San Diego-based company one step closer to joining the highly popular market for GLP-1s, which analysts say could grow into a $150 billion market by the end of the decade. Viking is one ...

Feb 11 (Reuters) - Viking Therapeutics (VKTX.O), opens new tab said on Wednesday it plans to test its experimental oral obesity drug in a late-stage study later this year. Shares of the company rose ...

Viking Therapeutics (VKTX) stock jumps as Wall Street welcomes the company's Q4 2025 results which includes pipeline updates on its obesity drug, VK2735. Read more here.

Viking Therapeutics Inc. said after-market hours Feb. 11 that it plans to advance its oral dual GLP-1/GIP receptor, VK-2735, into a phase III trial for obesity in the third quarter of 2026. VK-2735 is ...